Currently, there are 172.17M common shares owned by the public and among those 169.49M shares have been available to trade.
The company’s stock has a 5-day price change of -3.38% and 18.42% over the past three months. TDOC shares are trading -58.84% year to date (YTD), with the 12-month market performance down to -47.61% lower. It has a 12-month low price of $6.76 and touched a high of $22.54 over the same period. TDOC has an average intraday trading volume of 5.56 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -2.77%, 4.18%, and -24.78% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Teladoc Health Inc (NYSE: TDOC) shares accounts for 77.13% of the company’s 172.17M shares outstanding.
It has a market capitalization of $1.56B and a beta (3y monthly) value of 0.88. The earnings-per-share (ttm) stands at -$5.78. Price movements for the stock have been influenced by the stock’s volatility, which stands at 9.04% over the week and 6.44% over the month.
Earnings per share for the fiscal year are expected to decrease by -334.56%, and 84.47% over the next financial year.
Looking at the support for the TDOC, a number of firms have released research notes about the stock. Jefferies stated their Hold rating for the stock in a research note on September 17, 2024, with the firm’s price target at $8-$10. Cantor Fitzgerald coverage for the Teladoc Health Inc (TDOC) stock in a research note released on February 29, 2024 offered a Overweight rating with a price target of $22. Leerink Partners was of a view on February 26, 2024 that the stock is Market Perform, while DA Davidson gave the stock Neutral rating on January 17, 2024, issuing a price target of $33- $22. Barclays on their part issued Overweight rating on January 03, 2024.
